A Study Testing AOC 1020 to Improve Movement in Adults with Facioscapulohumeral Muscular Dystrophy
DenmarkStudy of AlloNK and rituximab with cyclophosphamide and fludarabine in adults with relapsing rheumatoid arthritis, inflammatory myopathies, systemic sclerosis, or Sjögren's disease
BulgariaStudy of intravenous AOC 1001 to evaluate long-term safety and effectiveness in patients with myotonic dystrophy type 1
DenmarkStudy on Long-Term Safety and Efficacy of VX-670 for Adults with Myotonic Dystrophy Type I
BelgiumStudy of ENTR-601-45 Safety and Effectiveness in Patients with Duchenne Muscular Dystrophy Who Can Skip Exon 45
BelgiumStudy on the Safety of CNTY-101 and Aldesleukin for Patients with Active Autoimmune Diseases: Lupus, Scleroderma, and Myositis
GermanyStudy of ENTR-601-44 in Children with Duchenne Muscular Dystrophy Who Are Eligible for Exon 44 Skipping Treatment
BelgiumStudy of SGT-003 Gene Therapy for Safety and Tolerability in Walking Males with Duchenne Muscular Dystrophy
ItalyStudy on the Long-Term Safety of Dazukibart in Patients with Idiopathic Inflammatory Myopathies, Including Dermatomyositis and Polymyositis
BulgariaStudy Comparing the Safety and Effectiveness of Mexiletine PR and Mexiletine IR for Adults with Non-Dystrophic Myotonias
BelgiumStudy of ADS-010 for Adults with Facioscapulohumeral Muscular Dystrophy Type 1
GermanyStudy on the Safety of MB-CART19.1 for Patients with Active Systemic Lupus Erythematosus, Systemic Sclerosis, or Dermatomyositis/Polymyositis
Germanypowered by
